Development and Evaluation of Self-Microemulsifying Drug Delivery System for Improving Oral Absorption of Poorly Water-Soluble Olaparib

The purpose of this study is to develop and evaluate a self-microemulsifying drug delivery system (SMEDDS) to improve the oral absorption of poorly water-soluble olaparib. Through the solubility test of olaparib in various oils, surfactants and co-surfactants, pharmaceutical excipients were selected. Self-emulsifying regions were identified by mixing the selected materials at various ratios, and a pseudoternary phase diagram was constructed by synthesizing these results. The various physicochemical properties of microemulsion incorporating olaparib were confirmed by investigating the morphology, particle size, zeta potential, drug content and stability. In addition, the improved dissolution and absorption of olaparib were also confirmed through a dissolution test and a pharmacokinetic study. An optimal microemulsion was generated in the formulation of Capmul® MCM 10%, Labrasol® 80% and PEG 400 10%. The fabricated microemulsions were well-dispersed in aqueous solutions, and it was also confirmed that they were maintained well without any problems of physical or chemical stability. The dissolution profiles of olaparib were significantly improved compared to the value of powder. Associated with the high dissolutions of olaparib, the pharmacokinetic parameters were also greatly improved. Taken together with the results mentioned above, the microemulsion could be an effective tool as a formulation for olaparib and other similar drugs.

[1]  R. Leblanc,et al.  Polyethylene glycol (PEG) derived carbon dots: Preparation and applications , 2020 .

[2]  I. Rabinowitch,et al.  Oral Administration of Artemisone for the Treatment of Schistosomiasis: Formulation Challenges and In Vivo Efficacy , 2020, Pharmaceutics.

[3]  B. Dong,et al.  Advances and perspectives of PARP inhibitors , 2019, Experimental Hematology & Oncology.

[4]  David J Brayden,et al.  Labrasol® is an efficacious intestinal permeation enhancer across rat intestine: Ex vivo and in vivo rat studies. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Upendra Bulbake,et al.  Preparation and Comparison of Oral Bioavailability for Different Nano-formulations of Olaparib , 2019, AAPS PharmSciTech.

[6]  Weifeng Lin,et al.  Poly-phosphocholinated Liposomes Form Stable Superlubrication Vectors. , 2019, Langmuir : the ACS journal of surfaces and colloids.

[7]  Diansong Zhou,et al.  Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients , 2018, Clinical Pharmacokinetics.

[8]  Shinn-Zong Lin,et al.  A PEG-Based Hydrogel for Effective Wound Care Management , 2018, Cell transplantation.

[9]  D. Hughes Patent Review of Manufacturing Routes to Recently Approved PARP Inhibitors: Olaparib, Rucaparib, and Niraparib , 2017 .

[10]  Thomas Lorenz,et al.  Novel strategies for the formulation and processing of poorly water‐soluble drugs , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[11]  R. Ghadi,et al.  BCS class IV drugs: Highly notorious candidates for formulation development , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[12]  C. Scott,et al.  Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum‐sensitive recurrent ovarian cancer , 2016, Asia-Pacific journal of clinical oncology.

[13]  Jiangnan Yu,et al.  Enhanced oral bioavailability of [6]-Gingerol-SMEDDS: Preparation, in vitro and in vivo evaluation , 2016 .

[14]  T. Kojima,et al.  A novel solubilization technique for poorly soluble drugs through the integration of nanocrystal and cocrystal technologies. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[15]  R. Plummer,et al.  An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib , 2016, Targeted Oncology.

[16]  A. Bauer-Brandl,et al.  Solubility enhancement of BCS Class II drug by solid phospholipid dispersions: Spray drying versus freeze-drying. , 2015, International journal of pharmaceutics.

[17]  V. Jannin,et al.  Development of self emulsifying lipid formulations of BCS class II drugs with low to medium lipophilicity. , 2015, International journal of pharmaceutics.

[18]  Surjyanarayan Mandal,et al.  Mucoadhesive microemulsion of ibuprofen: design and evaluation for brain targeting efficiency through intranasal route , 2015 .

[19]  A. Joshi,et al.  Self-microemulsifying drug delivery system (SMEDDS) – challenges and road ahead , 2015, Drug delivery.

[20]  N. Udupa,et al.  Role of Components in the Formation of Self-microemulsifying Drug Delivery Systems , 2015, Indian journal of pharmaceutical sciences.

[21]  R. Jachowicz,et al.  Preformulation Studies on Solid Self-Emulsifying Systems in Powder Form Containing Magnesium Aluminometasilicate as Porous Carrier , 2014, AAPS PharmSciTech.

[22]  Prakash Khadka,et al.  Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability , 2014 .

[23]  Sandeep Kalepu,et al.  Oral lipid-based drug delivery systems – an overview , 2013 .

[24]  Anette Müllertz,et al.  Lipid-based formulations for oral administration of poorly water-soluble drugs. , 2013, International journal of pharmaceutics.

[25]  Jaehwi Lee,et al.  Liposomal formulations for enhanced lymphatic drug delivery , 2013 .

[26]  Hywel D Williams,et al.  Strategies to Address Low Drug Solubility in Discovery and Development , 2013, Pharmacological Reviews.

[27]  D. Matei,et al.  Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.

[28]  Koichi Wada,et al.  Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. , 2011, International journal of pharmaceutics.

[29]  Z. A. Worku,et al.  Oral formulation strategies to improve solubility of poorly water-soluble drugs , 2011, Expert opinion on drug delivery.

[30]  A. Fahr,et al.  Skin penetration and deposition of carboxyfluorescein and temoporfin from different lipid vesicular systems: In vitro study with finite and infinite dosage application. , 2011, International journal of pharmaceutics.

[31]  D. Lindsay,et al.  Effects of artemisinin and Artemisia extracts on Haemonchus contortus in gerbils (Meriones unguiculatus). , 2011, Veterinary parasitology.

[32]  J. Benneyan,et al.  Impact of emulsion-based drug delivery systems on intestinal permeability and drug release kinetics. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[33]  Gordon L. Amidon,et al.  Prediction of Solubility and Permeability Class Membership: Provisional BCS Classification of the World’s Top Oral Drugs , 2009, The AAPS Journal.

[34]  K. Sawant,et al.  Self micro-emulsifying drug delivery system: formulation development and biopharmaceutical evaluation of lipophilic drugs. , 2009, Current drug delivery.

[35]  M. Singh,et al.  Exemestane Loaded Self-Microemulsifying Drug Delivery System (SMEDDS): Development and Optimization , 2008, AAPS PharmSciTech.

[36]  A. Narang,et al.  Stable drug encapsulation in micelles and microemulsions. , 2007, International journal of pharmaceutics.

[37]  A. Fahr,et al.  Drug delivery strategies for poorly water-soluble drugs , 2007, Expert opinion on drug delivery.

[38]  C. Pouton,et al.  Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[39]  W. Charman,et al.  Lipid-based vehicles for the oral delivery of poorly water soluble drugs , 1997 .

[40]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[41]  Pilar Ventosa-Andrés,et al.  DRUG SOLUBILITY : IMPORTANCE AND ENHANCEMENT TECHNIQUES , 2016 .

[42]  K. Anand,et al.  Techniques for solubility enhancement of poorly soluble drugs: an overview , 2012 .

[43]  V. Sharma,et al.  Enhancement of solubilization and bioavailability of poorly soluble drugs by physical and chemical modifications : A recent review , 2012 .

[44]  A. Chen,et al.  PARP inhibitor treatment in ovarian and breast cancer. , 2011, Current problems in cancer.

[45]  賢一 大河原,et al.  Self-microemulsifying drug delivery system (SMEDDS)製剤によるジゴキシンの吸収挙動改善 , 2010 .

[46]  G. Powis Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man. , 1983, Drug metabolism reviews.